Clinical Trial

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-11-06; most recent amendment 2026-02-19.
Trial Details
NCT Number NCT06679946
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Enrollment 700 participants
Start Date 2024-12-03
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20